24/7 Market News Snapshot 18 February, 2025 – Solid Biosciences Inc. Common Stock (NASDAQ:SLDB)

February 18, 2025

DENVER, Colo., 18 February, 2025 (247marketnews.com) – (Nasdaq:SLDB) are discussed in this article.
Solid Biosciences Inc. (Nasdaq:SLDB) is experiencing a significant boost in its market performance, with its stock soaring to $7.47 in pre-market trading, reflecting an impressive 85.33% increase from the prior close of $4.03. This surge has garnered notable trading volume, reaching 24.98 million shares, indicating heightened investor interest and momentum. The surge in stock price signals a potential breakout, attracting attention in the biotech sector.

Concurrently, the company has unveiled promising initial data from its Phase 1/2 INSPIRE DUCHENNE trial, which is focused on its next-generation gene therapy candidate, SGT-003, aimed at treating Duchenne muscular dystrophy (Duchenne). Recent findings from the trial reveal substantial advancements, with 90-day biopsy data from the first three participants demonstrating an average microdystrophin expression of 110%. These results correspond with significant improvements in critical biomarkers of muscle health, positioning SGT-003 as a potential breakthrough treatment option.

Dr. Bo Cumbo, President and CEO of Solid Biosciences, expressed optimism about these preliminary results, emphasizing the potential of SGT-003 as a best-in-class therapy, particularly highlighting early indications of cardiac benefits. The safety profile of SGT-003 has been reassuring, with no serious adverse events reported among the six participants treated; the findings are consistent with established parameters for AAV gene therapies.

As Solid Biosciences looks to expand participant enrollment to around 20 individuals by the conclusion of 2025, it is also planning to engage with regulatory authorities to discuss options for expedited approval of SGT-003. This commitment to innovation stands to make a significant impact in the field of genetic disease treatment, particularly in the battle against Duchenne muscular dystrophy.

Related news for (SLDB)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.